P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT)

Journal article

Open access

Peer reviewed

HemaSphere, Vol.6, pp.483-484

2022-06-01

Files and links (1)

url

https://doi.org/10.1097/01.hs9.0000845224.64123.95View

Published (Version of record) Open

2 Record Views

Title: P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT)
Creators: Mikkael Sekeres - Miller School of Medicine
Publication Details: HemaSphere, Vol.6, pp.483-484
Publisher: Wolters Kluwer
Academic Unit: UMMG Dept of Medicine - Hematology/Oncology; Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031757937902976